文献速递神经肿瘤

胶质母细胞瘤生存预测:荷兰神经外科质量登记处10年随访

Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry.
PubMed 文献 · J Neurooncol · 2025-05-23

基于荷兰神经外科质量登记处2012-2022年前瞻性队列7621例患者,分析胶质母细胞瘤生存及预后因素,开发两个实用预后模型,30天死亡率5.1%,2年生存率17.8%,中位生存10.4个月,模型C指数6个月0.704、2年0.721,尚待外部验证。

要点

  • 总体中位生存10.4个月,活检后4.6个月,切除后12.9个月。
  • 活检较切除死亡风险更高(HR 0.49,95%CI 0.47-0.52)。
  • MGMT启动子甲基化与辅助治疗与较低死亡率相关。

核心结论

  • 手术切除和辅助治疗改善生存,但预后仍差,年龄、病前状况、治疗和分子标志物影响生存,中心差异在预期范围内,较高手术量未改善结局,预后模型可能为临床医生提供信息,尚待外部验证。

研究设计与样本

  • 前瞻性队列研究,纳入荷兰12个中心2012-2022年7621例患者,数据来自荷兰神经外科质量登记处。

主要发现

  • 荷兰胶质母细胞瘤发病率为3.9/10万,总体30天死亡率为5.1%,2年生存率为17.8%。
  • 总体中位生存期为10.4个月,活检后为4.6个月,切除后为12.9个月。
  • 活检较切除死亡风险更高(HR 0.49,95%CI 0.47-0.52),术后并发症与更高死亡风险相关(HR 1.57,95%CI 1.39-1.79)。
  • MGMT启动子甲基化(HR 0.58,95%CI 0.53-0.63)和辅助治疗与较低死亡率相关。
  • 预后模型C指数:6个月为0.704,2年为0.721。

局限性

  • 预后模型尚待外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma is the most common and treatment-resistant primary malignant brain tumor, with high morbidity and mortality despite standard treatment protocols. This study aims to evaluate survival and prognostic factors, and introduce two pragmatic prognostic models to inform individualized, patient-centered decision-making, using a large Dutch registry. METHODS: We analyzed a prospective cohort of 7621 patients (2012-2022) in 12 Dutch centers via the Dutch Quality Registry Neurosurgery. Univariate analysis of prognostic factors, Kaplan-Meier survival curves, and funnel plots comparing center performance (30-day and 2-year mortality) were conducted. Two prognostic models using multivariate Cox regression were developed. RESULTS: Glioblastoma incidence was 3.9/100.000 in The Netherlands. Overall, 30-day mortality was 5.1% and 2-year survival 17.8%. Overall median survival was 10.4 months, with 4.6 months after biopsy and 12.9 months post-resection. Poorer survival correlated with older age, higher ASA classification, lower Karnofsky Performance Status, biopsy over resection (HR 0.49, 95% CI 0.47-0.52), and postoperative complications (HR 1.57 95% CI 1.39-1.79). MGMT promotor methylation (HR 0.58, 95% CI 0.53-0.63) and adjuvant treatment were linked to lower mortality. Treatment variation and outcomes were within expected ranges; surgical volume did not affect survival. The prognostic models had C-indices of 0.704 (6-month) and 0.721 (2-year). CONCLUSION: Surgical resection and adjuvant therapy improved survival, but prognosis remained poor. Age, premorbid condition, treatment and molecular markers influenced survival. Center variations were within expected range, and higher surgical volume did not improve outcomes. The developed prognostic models could potentially inform clinicians, pending external validation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. van Dijck JTJM, Ardon H, Balvers RK, et al. Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry. J Neurooncol. 2025. PMID: 40410639. doi:10.1007/s11060-025-05080-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。